Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 4/2015

01-04-2015 | Topic Paper

Update on the current evidence for Tm:YAG vapoenucleation of the prostate 2014

Authors: C. Netsch, T. Bach, T. R. W. Herrmann, A. J. Gross

Published in: World Journal of Urology | Issue 4/2015

Login to get access

Abstract

Introduction

To evaluate the current role of thulium vapoenucleation of the prostate (ThuVEP) for the treatment of benign prostatic obstruction (BPO).

Methods

A Medline search for randomized trials, case series, and comparative studies being published since the initial description of the ThuVEP procedure (2009–2014) was performed to assess the safety, the perioperative morbidity, the efficacy, and the durability of the technique.

Results

A total of 14 peer-reviewed original articles, seven case series [level of evidence (LOE) 4] and seven comparative studies (LOE 3b), have been identified. ThuVEP has been shown to be a size-independent, safe, efficacious, and durable procedure for the treatment of BPO in large, prospective, and retrospective series (LOE 4/3b). The feasibility and safety of the ThuVEP procedure has also been confirmed in patients at high cardiopulmonary risk on oral anticoagulants (LOE 4). It has also been demonstrated that the erectile function is not impaired by the ThuVEP procedure (LOE 4). However, published ThuVEP series are from very few centers of excellence not exceeding a LOE of 3b. Randomized controlled trials comparing ThuVEP with standard procedures for the treatment of BPO, namely transurethral resection of the prostate, open prostatectomy, or holmium laser enucleation of the prostate, have not been published so far.

Conclusions

ThuVEP appears to be a size-independent, safe, efficacious, and durable procedure for the treatment of BPO (LOE 4/3b). Multicentric PRT are however needed to define the current role of ThuVEP in the armamentarium of minimally invasive transurethral surgery of the prostate.
Literature
1.
Fraundorfer MR, Gilling PJ (1998) Holmium:YAG laser enucleation of the prostate combined with mechanical morcellation: preliminary results. Eur Urol 33:69–72CrossRefPubMed
2.
Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, Speakman MJ, Stief CG (2010) Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 58:384–397CrossRefPubMed
3.
Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S (2014) A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from Benign prostatic obstruction: an update. Eur Urol. pii:S0302-2838(14)00538-7. doi:10.​1016/​j.​eururo.​2014.​06.​017 [Epub ahead of print]
4.
Gilling PJ (2013) Laser enucleation is increasingly becoming the standard of care for treatment of benign prostatic hyperplasia of all sizes. Eur Urol 63:868–869CrossRefPubMed
5.
Bach T, Wendt-Nordahl G, Michel MS, Herrmann TR, Gross AJ (2009) Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate. World J Urol 27:541–545CrossRefPubMed
6.
Bach T, Netsch C, Haecker A, Michel MS, Herrmann TR, Gross AJ (2010) Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up. World J Urol 28:39–43CrossRefPubMed
7.
Fried NM, Murray KE (2005) High-power thulium fiber laser ablation of urinary tissues at.1.94 µm. J Endourol 19:25–31CrossRefPubMed
8.
9.
Herrmann TR, Liatsikos EN, Nagele U, Traxer O, Merseburger AS (2012) EAU guidelines panel on lasers, technologies. EAU guidelines on laser technologies. Eur Urol 61:783–795CrossRefPubMed
10.
Bach T, Xia SJ, Yang Y, Mattioli S, Watson GM, Gross AJ, Herrmann TR (2010) Thulium: YAG 2 mum cw laser prostatectomy: where do we stand? World J Urol 28:163–168CrossRefPubMed
11.
Hiraoka Y, Akimoto M (1989) Transurethral enucleation of benign prostatic hyperplasia. J Urol 142:1247–1250PubMed
12.
Bach T, Netsch C, Pohlmann L, Herrmann TR, Gross AJ (2011) Thulium:YAG vapoenucleation in large volume prostates. J Urol 186:2323–2327CrossRefPubMed
13.
Gross AJ, Netsch C, Knipper S, Hölzel J, Bach T (2013) Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. Eur Urol 63:859–867CrossRefPubMed
14.
Netsch C, Tiburtius C, Bach T, Knipper S, Gross AJ (2014) Association of prostate size and perioperative morbidity in thulium:YAG vapoenucleation of the prostate. Urol Int 93:22–28PubMed
15.
Hauser S, Rogenhofer S, Ellinger J, Strunk T, Müller SC, Fechner G (2012) Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage. Urol Int 88:390–394CrossRefPubMed
16.
Netsch C, Stoehrer M, Brüning M, Gabuev A, Bach T, Herrmann TR, Gross AJ (2014) Safety and effectiveness of thulium vapoenucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. World J Urol 32:165–172CrossRefPubMed
17.
Bach T, Herrmann TRW, Haecker A, Michel MS, Gross AJ (2009) Thulium:yttrium-aluminium-garnet laser prostatectomy in men with refractory urinary retention. BJU Int 104:361–364CrossRefPubMed
18.
Netsch C, Pohlmann L, Herrmann TR, Gross AJ, Bach T (2012) 120-W 2-µm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up. BJU Int 110:96–101CrossRefPubMed
19.
Netsch C, Bach T, Pohlmann L, Herrmann T, Gross AJ (2012) Comparison of 120-200 W 2 μm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate. J Endourol 26:224–229CrossRefPubMed
20.
Netsch C, Bach T, Herrmann TR, Gross AJ (2012) Thulium:YAG vapoenucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers. Asian J Androl 14:325–329CrossRefPubMedCentralPubMed
21.
Netsch C, Bach T, Herrmann TR, Neubauer O, Gross AJ (2013) Evaluation of the learning curve for thulium vapoenucleation of the prostate (ThuVEP) using a mentor-based approach. World J Urol 31:1231–1238CrossRefPubMed
22.
Tiburtius C, Knipper S, Gross AJ, Netsch C (2014) Impact of thulium vapoenucleation of the prostate on erectile function: a prospective analysis of 72 patients at 12-month follow-up. Urology 83:175–180CrossRefPubMed
23.
Netsch C, Engbert A, Bach T, Gross AJ Long-term outcome following thulium vapoenucleation of the prostate. World J Urol 2014 Feb 16 [Epub ahead of print]
24.
Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S, Montorsi F, Reich O, Stief C, Vavassori I (2009) A review of recent evidence (2006–2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol 55:1345–1357CrossRefPubMed
25.
Moody JA, Lingeman JE (2001) Holmium laser enucleation for prostate adenoma greater than 100 gm.: comparison to open prostatectomy. J Urol 165:459–462CrossRefPubMed
26.
Kuntz RM, Lehrich K (2002) Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.: a randomized prospective trial of 120 patients. J Urol 168:1465–1469CrossRefPubMed
27.
El-Hakim A, Elhilali MM (2002) Holmium laser enucleation of the prostate can be taught: the first learning experience. BJU Int 90:863–869CrossRefPubMed
28.
Shah HN, Mahajan AP, Sodha HS, Hegde S, Mohile PD, Bansal MB (2007) Prospective evaluation of the learning curve for holmium laser enucleation of the prostate. J Urol 177:1468–1474CrossRefPubMed
29.
Bach T, Huck N, Wezel F, Häcker A, Gross AJ, Michel MS (2010) 70 vs 120 W thulium:yttrium-aluminium-garnet 2 microm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex vivo evaluation. BJU Int 106:368–372CrossRefPubMed
Metadata
Title
Update on the current evidence for Tm:YAG vapoenucleation of the prostate 2014
Authors
C. Netsch
T. Bach
T. R. W. Herrmann
A. J. Gross
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 4/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-014-1417-z

Other articles of this Issue 4/2015

World Journal of Urology 4/2015 Go to the issue

Topic Paper

Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis

Invited Review

HoLEP has come of age

Invited Review

Update on Greenlight laser vaporization (PVP) 2014

Topic Paper

Bipolar plasma vaporization of the prostate: ready to replace GreenLight? A systematic review of randomized control trials

Topic Paper

Update on lasers in urology 2014: current assessment on holmium:yttrium–aluminum–garnet (Ho:YAG) laser lithotripter settings and laser fibers

Letter to the Editor

Thulium laser for the treatment of upper urinary tract carcinoma (UTUC)? Are we there, yet?